Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02148744 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis
A Phase 1 study, sponsored by Xencor.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT02148744 is a Phase 1 study that has completed, run by Xencor. The registered enrollment target is 72 participants.
The verdict
NCT02148744, a Phase 1 study, has completed, sponsored by Xencor.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
This first-in-human (FIH) study is a randomized, double-blinded, placebo-controlled, ascending dose study to investigate the safety, tolerability, and pharmacokinetics of XmAb7195 in adult healthy volunteers and in adult subjects with elevated IgE levels.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL XmAb7195
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2014-05 |
| Est. Completion | 2015-09-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02148744
The ClinicalTrials.gov registry entry for NCT02148744 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xencor, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02148744 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02148744 about?
NCT02148744 is a clinical study titled "Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis". This first-in-human (FIH) study is a randomized, double-blinded, placebo-controlled, ascending dose study to investigate the safety, tolerability, and pharmacokinetics of XmAb7195 in adult healthy volunteers and in adult subjects with elevated IgE levels.
What is the current status of trial NCT02148744?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2014-05. Estimated completion is 2015-09-21.
What interventions are being tested in trial NCT02148744?
The interventions under investigation include: Placebo (BIOLOGICAL), XmAb7195 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02148744?
This trial is sponsored by Xencor, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.